Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

Related Articles by Review for PubMed (Select 9516861)

1.

Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.

Kramer K, Cheung NK, Gerald WL, LaQuaglia M, Kushner BH, LeClerc JM, LeSauter L, Saragovi HU.

Eur J Cancer. 1997 Oct;33(12):2098-100.

PMID:
9516861
2.

Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group.

George RE, Variend S, Cullinane C, Cotterill SJ, McGuckin AG, Ellershaw C, Lunec J, Pearson AD; United Kingdom Children Cancer Study Group.

Med Pediatr Oncol. 2001 Jan;36(1):169-76. Review.

PMID:
11464876
3.

Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.

Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M.

J Clin Oncol. 1998 Oct;16(10):3286-94. Review.

PMID:
9779703
4.

Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.

Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B.

BMC Cancer. 2007 May 25;7:89. Review.

5.

[Biological markers for the prognosis of neuroblastoma: proposal of a method of analysis].

Combaret V, Delattre O, Bénard J, Favrot MC.

Bull Cancer. 1998 Mar;85(3):262-6. Review. French.

PMID:
9752317
6.

Differentiation and prognosis of neuroblastoma in correlation to the expression of CD44s.

Terpe HJ, Christiansen H, Gonzalez M, Berthold F, Lampert F.

Eur J Cancer. 1995;31A(4):549-52. Review.

PMID:
7576965
7.

Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?--An overview.

Tsuchida Y, Hemmi H, Inoue A, Obana K, Yang HW, Hayashi Y, Kanda N, Shimatake H.

Tumour Biol. 1996;17(2):65-74. Review.

PMID:
8658015
8.

Molecular basis for heterogeneity in human neuroblastomas.

Brodeur GM.

Eur J Cancer. 1995;31A(4):505-10. Review.

PMID:
7576954
9.

Gene profiling of high risk neuroblastoma.

Vasudevan SA, Nuchtern JG, Shohet JM.

World J Surg. 2005 Mar;29(3):317-24. Review.

PMID:
15706435
10.

Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype?

Scott D, Elsden J, Pearson A, Lunec J.

Cancer Lett. 2003 Jul 18;197(1-2):81-6. Review.

PMID:
12880964
11.
12.

[Molecular biology markers of neuroblastoma as the basis for a therapy concept].

Girgert R, Treuner J, Schweizer P.

Langenbecks Arch Chir Suppl Kongressbd. 1996;113:1053-5. Review. German.

PMID:
9101780
13.

Neuroblastoma stage IV-S.

Miale TD, Kirpekar K.

Med Oncol. 1994;11(3-4):89-100. Review.

PMID:
7633837
14.

Towards a turning point of neuroblastoma therapy.

Tonini GP, Nakagawara A, Berthold F.

Cancer Lett. 2012 Dec 30;326(2):128-34. doi: 10.1016/j.canlet.2012.08.017. Epub 2012 Aug 23. Review.

PMID:
22922304
15.

Correlation between morphologic and nonmorphologic prognostic markers of neuroblastoma.

Joshi VV, Tsongalis GJ.

Ann N Y Acad Sci. 1997 Sep 17;824:71-83. Review.

PMID:
9382456
16.

Familial neural crest tumours.

Robertson CM, Tyrrell JC, Pritchard J.

Eur J Pediatr. 1991 Sep;150(11):789-92. Review.

PMID:
1959543
17.

Why does stage 4s neuroblastoma regress spontaneously?

Pritchard J, Hickman JA.

Lancet. 1994 Sep 24;344(8926):869-70. Review. No abstract available.

PMID:
7916408
18.

Neuroblastoma.

Black CT, Atkinson JB.

Semin Pediatr Surg. 1997 Feb;6(1):2-10. Review. No abstract available.

PMID:
9117270
19.

Neuropeptides in neuroblastomas and ganglioneuromas.

Kogner P.

Prog Brain Res. 1995;104:325-38. Review. No abstract available.

PMID:
8552777
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk